1. Aging with Grace
   The Nun Study and the Science of Old Age
   Resource Type: Book
   
2. Alzheimer’s Weekly names ANAVEX 2-73 the number one most promising trial drug in Alzheimer’s disease and Anavex’s Phase I clinical program as “Trial o
   Sources News Release
   Resource Type: Article/Report/Letter
   Published: 2011
   ANAVEX 2-73 has been named 2010’s “most promising trial drug” by the editorial staff at Alzheimer’s Weekly.
3. Anavex appoints contract research organizations to initiate Phase I/IIa clinical programs, regulatory strategies in Alzheimer's disease
   Sources News Release
   Resource Type: Article/Report/Letter
   Published: 2010
   Anavex Life Sciences Corp signs a definitive master services agreement with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to begin clinical studies and regulatory filings for its lead compound for the treatment of Alzheimer#s.
4. Anavex comments on President Obama’s signing of National Alzheimer’s Project Act into law
   Sources News Release
   Resource Type: Article/Report/Letter
   Published: 2011
   Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today commented on President Obama’s signing of the National Alzheimer’s Project Act (NAPA) into law. The passage of this landmark legislation lays the foundation for the first coordinated national
5. Anavex files Phase I regulatory submission for ANAVEX 2-73 in Alzheimer’s disease
   Sources News Release
   Resource Type: Article/Report/Letter
   Published: 2011
   Anavex Life Sciences Corp. has filed regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer
6. Anavex to present at Rodman & Renshaw Healthcare Conference September 13 in New York
   Sources News Release
   Resource Type: Article/Report/Letter
   Published: 2010
   Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that Dr. Cameron Durrant, the company#s Executive Chairman, will be presenting at the Rodman & Renshaw 12th Annual Healthcare Conference at 4:45 pm ET on Monday, September 13
7. Sources welcomes Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert
   Sources News Release
   Resource Type: Article/Report/Letter
   Published: 2010
   Sources welcomes a new member: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert.

Experts on Alzheimer Disease/Research in the Sources Directory

1. The Cochrane Collaboration/The Cochrane Library